Overview

PK and Drug Interaction Study of Utidelone Plus Capecitabine in Patients With Advanced Breast Cancer

Status:
Recruiting
Trial end date:
2021-12-31
Target enrollment:
Participant gender:
Summary
This trial is an open, multi-center, phase Ic clinical study on the pharmacokinetics and drug interactions of utidelone injection combined with capecitabine in patients with recurrent and metastatic breast cancer. The purpose of this trial is: 1. To evaluate the pharmacokinetic characteristics of continuous intravenous administration of utidelone. 2. To evaluate the drug interaction of utidelone and capecitabine.
Phase:
Phase 1
Details
Lead Sponsor:
Beijing Biostar Technologies, Ltd
Collaborator:
Chengdu Biostar Pharmaceuticals, Ltd
Treatments:
Capecitabine